---
document_datetime: 2025-12-02 05:21:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/neparvis.html
document_name: neparvis.html
version: success
processing_time: 0.1531747
conversion_datetime: 2025-12-28 18:09:42.235063
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Neparvis

[RSS](/en/individual-human-medicine.xml/67040)

##### Authorised

This medicine is authorised for use in the European Union

sacubitril / valsartan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Neparvis](#news-on)
- [More information on Neparvis](#more-information-on-neparvis-858)
- [More information on Neparvis](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Neparvis is a heart medicine used in adults with chronic (long-term) heart failure who have symptoms of the disease and reduced ejection fraction (a measure of how well the heart pumps blood). The medicine is also used in adolescents and children from 1 year of age with chronic heart failure who have symptoms of the disease and left ventricular systolic dysfunction (a problem affecting the left side of the heart).

Heart failure is the inability of the heart to pump enough blood around the body.

Neparvis contains the active substances sacubitril and valsartan.

This medicine is the same as Entresto, which is already authorised in the EU. The company that makes Neparvis has agreed that its scientific data can be used for Neparvis ('informed consent').

Expand section

Collapse section

## How is Neparvis used?

Neparvis can only be obtained with a prescription. The medicine is available as tablets and granules to be taken by month twice a day.

For more information about using Neparvis, see the package leaflet or contact your doctor or pharmacist.

## How does Neparvis work?

The two active substances in Neparvis, sacubitril and valsartan, work in different ways. Sacubitril blocks the breakdown of natriuretic peptides produced in the body. Natriuretic peptides cause sodium and water to pass into the urine thereby reducing the strain on the heart. They also reduce blood pressure and protect the heart from developing fibrosis (scar tissue) that occurs in heart failure.

Valsartan is an 'angiotensin-II-receptor antagonist', which means that it blocks the action of a hormone called angiotensin II. The effects of angiotensin II can be harmful in patients with heart failure. By blocking the receptors (targets) to which angiotensin II normally attaches, valsartan stops the hormone's harmful effects on the heart and also reduces blood pressure by allowing blood vessels to widen.

## What benefits of Neparvis have been shown in studies?

Neparvis has been shown to be effective at treating heart failure in adults in one main study. In the study, Neparvis was compared to enalapril, another medicine used for heart failure. Patients in the study had long-term heart failure with symptoms of the disease and reduced ejection fraction (the proportion of blood leaving the heart). In the group treated with Neparvis, 21.8% (914 of 4,187) of patients either died as a result of heart and circulation problems or were admitted to hospital with heart failure compared to 26.5% (1,117 of 4,212) of patients treated with enalapril. In general, patients were monitored for about 27 months, during which they took the medicine for about 24 months on average. The study was stopped early because there was compelling evidence that Neparvis was more effective than enalapril.

A study involving children and adolescents showed that the way Neparvis behaves in the body in people below 18 years old is similar to that seen in adults. In addition, Neparvis led to similar reductions across age groups in the blood levels of NT-proBNP. Patients with heart failure have raised levels of NT-proBNP, substances made by the heart. A reduced level of NT-proBNP is associated with a better outcome for patients.

In addition, the study comparing Neparvis with enalapril in 377 patients aged 1 month to below 18 years with heart failure due to systemic left ventricle systolic dysfunction. The main measure of effectiveness was the likelihood of a better outcome after one year of treatment compared with that in the other treatment group (based on the ranking of various events such as death, urgent heart transplant or worsening of symptoms). The results did not show that Neparvis was more effective than enalapril in terms of this measure. However, in both the Neparvis and enalapril groups, there were relevant improvements in symptoms and quality of life measures.

## What are the risks associated with Neparvis?

For the full list of side effects and restrictions with Neparvis, see the package leaflet.

The most common side effects with Neparvis in adults (which may affect more than 1 in 10 people) include hyperkalaemia (high blood potassium levels), hypotension (low blood pressure) and renal impairment (kidneys working less well). A potentially severe side effect, angioedema (rapid swelling of deeper skin tissues as well as the tissues around the throat, causing breathing difficulty) can occur uncommonly (in up to 1 in 100 people).

Side effects in children and adolescents are similar to those seen in adults.

Neparvis must not be taken with medicines known as ACE inhibitors (to treat heart failure and high blood pressure) or with medicines containing aliskiren (to treat high blood pressure) in patients who have diabetes or reduced kidney function. It must not be taken by patients who have suffered angioedema, those who have severe liver disease or by women who are pregnant.

## Why is Neparvis approved?

The European Medicines Agency decided that the benefits of Neparvis are greater than its risks and it can be authorised for use in the EU. The main study found that in adults Neparvis reduced deaths from heart and circulation problems or hospital admissions for heart failure. An additional study has shown that Neparvis is expected to provide clinically meaningful benefits to children and adolescents with symptomatic heart failure due to systemic left ventricular dysfunction.

The serious side effects with Neparvis in the main study were similar to those of enalapril, another medicine used for heart failure. Valsartan, one of the active substances in the medicine, is well established for the treatment of high blood pressure and heart failure; its side effects are well known.

## What measures are being taken to ensure the safe and effective use of Neparvis?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Neparvis have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Neparvis are continuously monitored. Suspected side effects reported with Neparvis are carefully evaluated and any necessary action taken to protect patients.

## Other information about Neparvis

Neparvis was granted a marketing authorisation valid throughout the European Union on 26 May 2016.

Further information on Neparvis can be found on the Agency's website: [ema.europa.eu/medicines/human/EPAR/neparvis](/en/medicines/human/EPAR/neparvis) .

This overview was last updated in 04-2023.

Neparvis : EPAR - Summary for the public

Reference Number: EMA/183671/2023

English (EN) (96.57 KB - PDF)

**First published:** 13/06/2016

**Last updated:** 22/06/2023

[View](/en/documents/overview/neparvis-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-993)

български (BG) (120.88 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/bg/documents/overview/neparvis-epar-summary-public_bg.pdf)

español (ES) (97.9 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/es/documents/overview/neparvis-epar-summary-public_es.pdf)

čeština (CS) (118.05 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/cs/documents/overview/neparvis-epar-summary-public_cs.pdf)

dansk (DA) (97.29 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/da/documents/overview/neparvis-epar-summary-public_da.pdf)

Deutsch (DE) (98.43 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/de/documents/overview/neparvis-epar-summary-public_de.pdf)

eesti keel (ET) (96.57 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/et/documents/overview/neparvis-epar-summary-public_et.pdf)

ελληνικά (EL) (130.03 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/el/documents/overview/neparvis-epar-summary-public_el.pdf)

français (FR) (98.56 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/fr/documents/overview/neparvis-epar-summary-public_fr.pdf)

hrvatski (HR) (111.91 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/hr/documents/overview/neparvis-epar-summary-public_hr.pdf)

italiano (IT) (97.62 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/it/documents/overview/neparvis-epar-summary-public_it.pdf)

latviešu valoda (LV) (127.08 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/lv/documents/overview/neparvis-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (115.69 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/lt/documents/overview/neparvis-epar-summary-public_lt.pdf)

magyar (HU) (113.13 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/hu/documents/overview/neparvis-epar-summary-public_hu.pdf)

Malti (MT) (117.16 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/mt/documents/overview/neparvis-epar-summary-public_mt.pdf)

Nederlands (NL) (98.11 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/nl/documents/overview/neparvis-epar-summary-public_nl.pdf)

polski (PL) (117.58 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/pl/documents/overview/neparvis-epar-summary-public_pl.pdf)

português (PT) (97.89 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/pt/documents/overview/neparvis-epar-summary-public_pt.pdf)

română (RO) (114.45 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/ro/documents/overview/neparvis-epar-summary-public_ro.pdf)

slovenčina (SK) (115.05 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/sk/documents/overview/neparvis-epar-summary-public_sk.pdf)

slovenščina (SL) (112.43 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/sl/documents/overview/neparvis-epar-summary-public_sl.pdf)

Suomi (FI) (97.27 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/fi/documents/overview/neparvis-epar-summary-public_fi.pdf)

svenska (SV) (97.09 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

22/06/2023

[View](/sv/documents/overview/neparvis-epar-summary-public_sv.pdf)

Neparvis : EPAR - Risk management plan

English (EN) (547.41 KB - PDF)

**First published:** 07/12/2020

**Last updated:** 10/03/2025

[View](/en/documents/rmp/neparvis-epar-risk-management-plan_en.pdf)

## Product information

Neparvis : EPAR - Product Information

English (EN) (1.26 MB - PDF)

**First published:** 13/06/2016

**Last updated:** 14/05/2025

[View](/en/documents/product-information/neparvis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-237)

български (BG) (978.92 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/bg/documents/product-information/neparvis-epar-product-information_bg.pdf)

español (ES) (3.33 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/es/documents/product-information/neparvis-epar-product-information_es.pdf)

čeština (CS) (993.92 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/cs/documents/product-information/neparvis-epar-product-information_cs.pdf)

dansk (DA) (726.54 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/da/documents/product-information/neparvis-epar-product-information_da.pdf)

Deutsch (DE) (3.39 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/de/documents/product-information/neparvis-epar-product-information_de.pdf)

eesti keel (ET) (2.92 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/et/documents/product-information/neparvis-epar-product-information_et.pdf)

ελληνικά (EL) (3.44 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/el/documents/product-information/neparvis-epar-product-information_el.pdf)

français (FR) (946.83 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/fr/documents/product-information/neparvis-epar-product-information_fr.pdf)

hrvatski (HR) (3.6 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/hr/documents/product-information/neparvis-epar-product-information_hr.pdf)

íslenska (IS) (2.93 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/is/documents/product-information/neparvis-epar-product-information_is.pdf)

italiano (IT) (3.31 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/it/documents/product-information/neparvis-epar-product-information_it.pdf)

latviešu valoda (LV) (3.34 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/lv/documents/product-information/neparvis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (3.63 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/lt/documents/product-information/neparvis-epar-product-information_lt.pdf)

magyar (HU) (939.07 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/hu/documents/product-information/neparvis-epar-product-information_hu.pdf)

Malti (MT) (4.44 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/mt/documents/product-information/neparvis-epar-product-information_mt.pdf)

Nederlands (NL) (3.02 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/nl/documents/product-information/neparvis-epar-product-information_nl.pdf)

norsk (NO) (2.94 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/no/documents/product-information/neparvis-epar-product-information_no.pdf)

polski (PL) (3.5 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/pl/documents/product-information/neparvis-epar-product-information_pl.pdf)

português (PT) (3.59 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/pt/documents/product-information/neparvis-epar-product-information_pt.pdf)

română (RO) (3.64 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/ro/documents/product-information/neparvis-epar-product-information_ro.pdf)

slovenčina (SK) (4.21 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/sk/documents/product-information/neparvis-epar-product-information_sk.pdf)

slovenščina (SL) (903.39 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/sl/documents/product-information/neparvis-epar-product-information_sl.pdf)

Suomi (FI) (3.18 MB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/fi/documents/product-information/neparvis-epar-product-information_fi.pdf)

svenska (SV) (710.16 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

14/05/2025

[View](/sv/documents/product-information/neparvis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010438/202407 23/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Neparvis : EPAR - All Authorised presentations

English (EN) (110.51 KB - PDF)

**First published:** 13/06/2016

**Last updated:** 21/03/2024

[View](/en/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-212)

български (BG) (78.79 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/bg/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_bg.pdf)

español (ES) (174.08 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/es/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (111.85 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/cs/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (113.06 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/da/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (176.51 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/de/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (107.9 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/et/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (186.01 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/el/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_el.pdf)

français (FR) (105.79 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/fr/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (113.28 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/hr/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (108.01 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/is/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_is.pdf)

italiano (IT) (109.77 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/it/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (114.94 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/lv/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (180.34 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/lt/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (119.1 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/hu/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (116.09 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/mt/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (109.01 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/nl/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (110.61 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/no/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_no.pdf)

polski (PL) (113.19 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/pl/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_pl.pdf)

português (PT) (110.22 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/pt/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_pt.pdf)

română (RO) (177.07 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/ro/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (113.85 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/sk/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (177.67 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/sl/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (111.98 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/fi/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (109.77 KB - PDF)

**First published:**

13/06/2016

**Last updated:**

21/03/2024

[View](/sv/documents/all-authorised-presentations/neparvis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Neparvis Active substance

- sacubitril
- valsartan

International non-proprietary name (INN) or common name

- sacubitril
- valsartan

Therapeutic area (MeSH) Heart Failure Anatomical therapeutic chemical (ATC) code C09DX04

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

**Paediatric heart failure**

Neparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).

**Adult heart failure**

Neparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/004343 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 31/03/2016 Marketing authorisation issued 26/05/2016 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Neparvis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.2 KB - PDF)

**First published:** 24/02/2025

[View](/en/documents/procedural-steps-after/neparvis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Neparvis : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (264.98 KB - PDF)

**First published:** 05/10/2016

**Last updated:** 14/05/2025

[View](/en/documents/procedural-steps-after/neparvis-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Neparvis-PAM-0000248986 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-1894978

English (EN) (468.19 KB - PDF)

**First published:** 23/06/2025

[View](/en/documents/variation-report/neparvis-pam-0000248986-epar-assessment-report_en.pdf)

Neparvis-H-C-PSUSA-00010438-202407 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/59987/2025

English (EN) (93.54 KB - PDF)

**First published:** 14/05/2025

[View](/en/documents/scientific-conclusion/neparvis-h-c-psusa-00010438-202407-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Neparvis-H-C-4343-WS-2738 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/16969/2025

English (EN) (1.06 MB - PDF)

**First published:** 15/01/2025

[View](/en/documents/variation-report/neparvis-h-c-4343-ws-2738-epar-assessment-report-variation_en.pdf)

Neparvis : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/286177/2023

English (EN) (95.83 KB - PDF)

**First published:** 22/06/2023

[View](/en/documents/pip-compliance/neparvis-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Neparvis-H-C-4343-X-0042 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/172237/2023

English (EN) (3.74 MB - PDF)

**First published:** 22/06/2023

[View](/en/documents/variation-report/neparvis-h-c-4343-x-0042-epar-assessment-report-extension_en.pdf)

CHMP post-authorisation summary of positive opinion for Neparvis (X-42-G)

Adopted

Reference Number: EMA/CHMP/130048/2023

English (EN) (89.18 KB - PDF)

**First published:** 31/03/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-neparvis-x-42-g_en.pdf)

Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

English (EN) (119.28 KB - PDF)

**First published:** 05/07/2021

[View](/en/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

[Other languages (22)](#file-language-dropdown-239)

български (BG) (145.18 KB - PDF)

**First published:**

05/07/2021

[View](/bg/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_bg.pdf)

español (ES) (125.85 KB - PDF)

**First published:**

05/07/2021

[View](/es/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_es.pdf)

čeština (CS) (139.02 KB - PDF)

**First published:**

05/07/2021

[View](/cs/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_cs.pdf)

dansk (DA) (126.81 KB - PDF)

**First published:**

05/07/2021

[View](/da/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_da.pdf)

Deutsch (DE) (131.05 KB - PDF)

**First published:**

05/07/2021

[View](/de/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_de.pdf)

eesti keel (ET) (123.85 KB - PDF)

**First published:**

05/07/2021

[View](/et/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_et.pdf)

ελληνικά (EL) (139.5 KB - PDF)

**First published:**

05/07/2021

[View](/el/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_el.pdf)

français (FR) (127.12 KB - PDF)

**First published:**

05/07/2021

[View](/fr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fr.pdf)

hrvatski (HR) (142.87 KB - PDF)

**First published:**

05/07/2021

[View](/hr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hr.pdf)

italiano (IT) (126.56 KB - PDF)

**First published:**

05/07/2021

[View](/it/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_it.pdf)

latviešu valoda (LV) (147.7 KB - PDF)

**First published:**

05/07/2021

[View](/lv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lv.pdf)

lietuvių kalba (LT) (148.34 KB - PDF)

**First published:**

05/07/2021

[View](/lt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lt.pdf)

magyar (HU) (137.17 KB - PDF)

**First published:**

05/07/2021

[View](/hu/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hu.pdf)

Malti (MT) (151.21 KB - PDF)

**First published:**

05/07/2021

[View](/mt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_mt.pdf)

Nederlands (NL) (127.53 KB - PDF)

**First published:**

05/07/2021

[View](/nl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_nl.pdf)

polski (PL) (137.7 KB - PDF)

**First published:**

05/07/2021

[View](/pl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pl.pdf)

português (PT) (128.87 KB - PDF)

**First published:**

05/07/2021

[View](/pt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pt.pdf)

română (RO) (143.59 KB - PDF)

**First published:**

05/07/2021

[View](/ro/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_ro.pdf)

slovenčina (SK) (135.07 KB - PDF)

**First published:**

05/07/2021

[View](/sk/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sk.pdf)

slovenščina (SL) (149.74 KB - PDF)

**First published:**

05/07/2021

[View](/sl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sl.pdf)

Suomi (FI) (125.84 KB - PDF)

**First published:**

05/07/2021

[View](/fi/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fi.pdf)

svenska (SV) (126.99 KB - PDF)

**First published:**

05/07/2021

[View](/sv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sv.pdf)

Neparvis : EPAR - EMEA/H/C/PSUSA/00010438/202007 - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

English (EN) (119.1 KB - PDF)

**First published:** 11/06/2021

**Last updated:** 11/06/2021

[View](/en/documents/scientific-conclusion/neparvis-epar-emeahcpsusa00010438202007-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

Reference Number: EMA/47245/2021

English (EN) (362.31 KB - PDF)

**First published:** 02/03/2021

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

Neparvis-H-C-4343-A31-0020 : EPAR - Scientific conclusions

English (EN) (99.42 KB - PDF)

**First published:** 21/05/2019

[View](/en/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_en.pdf)

[Other languages (22)](#file-language-dropdown-646)

български (BG) (136.15 KB - PDF)

**First published:**

21/05/2019

[View](/bg/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_bg.pdf)

español (ES) (98.31 KB - PDF)

**First published:**

21/05/2019

[View](/es/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_es.pdf)

čeština (CS) (131.08 KB - PDF)

**First published:**

21/05/2019

[View](/cs/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_cs.pdf)

dansk (DA) (96.12 KB - PDF)

**First published:**

21/05/2019

[View](/da/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_da.pdf)

Deutsch (DE) (100.2 KB - PDF)

**First published:**

21/05/2019

[View](/de/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_de.pdf)

eesti keel (ET) (94.4 KB - PDF)

**First published:**

21/05/2019

[View](/et/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_et.pdf)

ελληνικά (EL) (142.79 KB - PDF)

**First published:**

21/05/2019

[View](/el/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_el.pdf)

français (FR) (97.56 KB - PDF)

**First published:**

21/05/2019

[View](/fr/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_fr.pdf)

hrvatski (HR) (125.02 KB - PDF)

**First published:**

21/05/2019

[View](/hr/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_hr.pdf)

italiano (IT) (95.54 KB - PDF)

**First published:**

21/05/2019

[View](/it/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_it.pdf)

latviešu valoda (LV) (130.68 KB - PDF)

**First published:**

21/05/2019

[View](/lv/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_lv.pdf)

lietuvių kalba (LT) (130.84 KB - PDF)

**First published:**

21/05/2019

[View](/lt/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_lt.pdf)

magyar (HU) (119.82 KB - PDF)

**First published:**

21/05/2019

[View](/hu/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_hu.pdf)

Malti (MT) (133.78 KB - PDF)

**First published:**

21/05/2019

[View](/mt/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_mt.pdf)

Nederlands (NL) (99.3 KB - PDF)

**First published:**

21/05/2019

[View](/nl/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_nl.pdf)

polski (PL) (130.65 KB - PDF)

**First published:**

21/05/2019

[View](/pl/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_pl.pdf)

português (PT) (96.47 KB - PDF)

**First published:**

21/05/2019

[View](/pt/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_pt.pdf)

română (RO) (128.25 KB - PDF)

**First published:**

21/05/2019

[View](/ro/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_ro.pdf)

slovenčina (SK) (119.14 KB - PDF)

**First published:**

21/05/2019

[View](/sk/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_sk.pdf)

slovenščina (SL) (124.14 KB - PDF)

**First published:**

21/05/2019

[View](/sl/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_sl.pdf)

Suomi (FI) (97.12 KB - PDF)

**First published:**

21/05/2019

[View](/fi/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_fi.pdf)

svenska (SV) (96.85 KB - PDF)

**First published:**

21/05/2019

[View](/sv/documents/scientific-conclusion/neparvis-h-c-4343-a31-0020-epar-scientific-conclusions_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report

Adopted

Reference Number: EMA/217823/2019

English (EN) (531.32 KB - PDF)

**First published:** 02/05/2019

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf)

## Initial marketing authorisation documents

Neparvis : EPAR - Public assessment report

Adopted

Reference Number: EMA/255018/2016

English (EN) (228.47 KB - PDF)

**First published:** 13/06/2016

**Last updated:** 13/06/2016

[View](/en/documents/assessment-report/neparvis-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Neparvis

Adopted

Reference Number: EMA/204025/2016

English (EN) (67.89 KB - PDF)

**First published:** 01/04/2016

**Last updated:** 01/04/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-neparvis_en.pdf)

#### News on Neparvis

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023) 31/03/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 29 March - 1 April 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-29-march-1-april-2016) 01/04/2016

#### More information on Neparvis

- [Valsartan containing medicinal products: Article 31 referrals](/en/medicines/human/referrals/sartan-medicines)

#### More information on Neparvis

- [Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - referral](/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 23/06/2025

## Share this page

[Back to top](#main-content)